Table 2

Association of leukocyte subsets with nerve conduction velocity (NCV) sum score (N=850)

Leukocyte subset		Model 1			Model 2			Model 3
Leukocyte subset		β	95% CI	P value	β	95% CI	P value	β	95% CI	P value
Innate immunity	Monocytes	−0.004	(−0.029 to 0.020)	0.745	−0.010	(−0.034 to 0.015)	0.450	−0.007	(−0.032 to 0.017)	0.539
	Basophils	−0.096	(−0.190 to –0.003)	0.042	−0.115	(−0.208 to −0.022)	0.015	−0.116	(−0.210 to −0.023)	0.014
	Eosinophils	−0.005	(−0.031 to 0.020)	0.670	−0.006	(−0.032 to 0.020)	0.642	−0.008	(−0.033 to 0.017)	0.538
	Neutrophils	−0.005	(−0.011 to 0.001)	0.072	−0.004	(−0.011 to 0.002)	0.172	−0.002	(−0.009 to 0.003)	0.399
Adaptive immunity	Lymphocytes	0.007	(0.001 to 0.014)	0.036	0.006	(−0.001 to 0.013)	0.076	0.004	(−0.003 to 0.011)	0.225
	T cells	0.001	(−0.004 to 0.007)	0.565	0.002	(−0.004 to 0.008)	0.441	0.002	(−0.003 to 0.008)	0.326
	CD4⁺ T cells	−0.007	(−0.011 to –0.002)	0.001	−0.006	(−0.011 to −0.002)	0.006	−0.006	(−0.010 to –0.001)	0.005
	CD8⁺ T cells	0.006	(0.001 to 0.011)	0.007	0.006	(0.001 to 0.011)	0.023	0.005	(0.001 to 0.010)	0.022
	T reg cells	−0.009	(−0.036 to 0.017)	0.499	−0.014	(−0.041 to 0.012)	0.293	−0.011	(−0.038 to 0.015)	0.394
	B cells	−0.001	(−0.011 to 0.008)	0.827	−0.001	(−0.011 to 0.009)	0.777	−0.002	(−0.012 to 0.007)	0.585

NCV sum score is defined as a continuous variable calculated based on NCV available for at least one nerve.
Model 1: adjusted for sex and age (based on 850 participants).
Model 2: adjusted for model 1+glucose metabolism status (based on 847 participants).
Model 3: adjusted for model 2+BMI, HbA1c, total cholesterol, triglycerides, eGFR, history of hypertension, history of CVD, glucose-lowering drugs, lipid-lowering drugs, non-steroidal anti-inflammatory drugs, smoking and alcohol consumption (based on 845 participants).
BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c.